Astellas US promotes Jeffrey Bloss to SVP of medical affairs for the Americas

16 April 2014
astellas-location-big

The US subsidiary of Japanese drug major Astellas Pharma (TYO: 4503) announced that Jeffrey Bloss has been promoted to the position of senior vice president, medical affairs Americas, Astellas Scientific and Medical Affairs (ASMA), effective April 1. Dr Bloss will serve as a member of the Astellas US management committee.

"Jeff has been a key partner and thought leader to the global medical affairs function since joining Astellas in 2012," said Masao Yoshida, chief executive of Astellas US.

Since coming to Astellas in October of 2012, Dr Bloss has been responsible for leading the America's regional medical affairs function, including medical information and publications, therapeutic area medical directors, medical scientific liaisons, health economy and clinical outcomes research, independent medical education and medical affairs operations. Dr Bloss has also assumed direct oversight of the medical affairs functions in Canada and Brazil, and he has established strong collaborations with other functions throughout the company to optimize medical/scientific value across the product lifecycle.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

More on this story...





Today's issue

Company Spotlight





More Features in Pharmaceutical